

Renata Ursu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7240112/publications.pdf>

Version: 2024-02-01

29
papers

1,297
citations

567281

15
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

2243
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. <i>European Journal of Cancer</i> , 2017, 73, 1-8.	2.8	397
2	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. <i>Neuro-Oncology</i> , 2010, 12, 401-408.	1.2	180
3	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOV19). <i>European Journal of Cancer</i> , 2020, 141, 62-81.	2.8	122
4	Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. <i>Neuro-Oncology</i> , 2012, 14, 491-495.	1.2	83
5	Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma: A phase II multicentric, randomised study. <i>European Journal of Cancer</i> , 2017, 73, 30-37.	2.8	68
6	Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. <i>Scientific Reports</i> , 2020, 10, 18997.	3.3	59
7	Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. <i>Journal of Neuro-Oncology</i> , 2018, 136, 565-576.	2.9	47
8	Evolution of the Karnofsky Performance Status throughout life in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 122, 567-573.	2.9	39
9	Steroid-sparing effects of angiotensin II inhibitors in glioblastoma patients. <i>European Journal of Neurology</i> , 2012, 19, 1337-1342.	3.3	35
10	Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?. <i>Journal of Neuro-Oncology</i> , 2017, 135, 285-297.	2.9	35
11	Steroid requirements during radiotherapy for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2010, 100, 89-94.	2.9	29
12	Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma. <i>European Journal of Neurology</i> , 2015, 22, 1304-1309.	3.3	28
13	Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial. <i>Cancer Science</i> , 2015, 106, 1212-1218.	3.9	24
14	Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients. , 2020, 8, e001034.		20
15	Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study. <i>Neuro-Oncology</i> , 2021, 23, 1569-1575.	1.2	20
16	Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients. <i>Journal of Neurology</i> , 2016, 263, 524-530.	3.6	19
17	Immunotherapeutic Approach with Oligodeoxynucleotides Containing CpG Motifs (CpG-ODN) in Malignant Glioma. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 95-108.	1.6	17
18	Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma: a randomised multicentre trial (ASTER trial). An ANOCEF study. <i>European Journal of Cancer</i> , 2019, 109, 129-136.	2.8	13

#	ARTICLE	IF	CITATIONS
19	Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study. <i>Psycho-Oncology</i> , 2018, 27, 1861-1864.	2.3	12
20	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	2.4	12
21	Superficial siderosis of the central nervous system: a rare cause of dementia with therapeutic consequences. <i>Age and Ageing</i> , 2012, 41, 275-277.	1.6	8
22	SARS-CoV-2 infection in patients with primary central nervous system lymphoma. <i>Journal of Neurology</i> , 2021, 268, 3072-3080.	3.6	7
23	Varicella Zoster Virus vasculopathy in a patient treated with immune checkpoint inhibitor for lung cancer. <i>Revue Neurologique</i> , 2019, 175, 95-97.	1.5	6
24	Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. <i>Cancers</i> , 2020, 12, 2635.	3.7	5
25	Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. <i>Journal of Neurology</i> , 2021, 268, 2515-2522.	3.6	4
26	Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy. <i>Journal of NeuroVirology</i> , 2021, 27, 94-100.	2.1	2
27	Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab078.	0.7	2
28	Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: A case report. <i>Revue Neurologique</i> , 2021, , .	1.5	2
29	Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3065-3065.	1.6	0